SCHEDULE: OrbiMed's Stake in ArriVent BioPharma Dips to 7.5%

OrbiMed Advisors and affiliated entities reported a decrease in their beneficial ownership of ArriVent BioPharma, Inc. common stock to 7.5% due to an increase in the issuer's outstanding shares.

Summary

• OrbiMed Advisors LLC and its affiliates (OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., and OrbiMed Advisors IV Limited) filed an Amendment No. 1 to their Schedule 13D for ArriVent BioPharma, Inc.
• The filing reports a decrease in their aggregate beneficial ownership of ArriVent BioPharma's common stock by more than 1%.
• This decrease is attributed to an increase in the total number of outstanding shares of ArriVent BioPharma, Inc., not a sale by OrbiMed.
• As of the filing date, OrbiMed Advisors LLC beneficially owns 3,027,328 shares, representing 7.5% of the outstanding common stock.
• The total outstanding shares of ArriVent BioPharma, Inc. are reported as 40,568,944, based on the Issuer's Quarterly Report on Form 10-Q filed on August 11, 2025.
• OrbiMed's investment in ArriVent BioPharma is for investment purposes, not to acquire control, though their director on the board can influence.

Sentiment

Score: 6

Explanation: The filing is largely neutral, as it primarily reports a technical adjustment in percentage ownership due to share dilution rather than a divestment by the investor. The continued significant stake by OrbiMed, a specialized healthcare investor, is a positive signal, but the underlying dilution for existing shareholders is a slight negative.

Positives

• OrbiMed, a significant institutional investor, maintains a substantial 7.5% stake in ArriVent BioPharma, indicating continued long-term investment interest.
• The decrease in percentage ownership was due to an increase in the issuer's outstanding shares, suggesting the company successfully raised capital or issued shares, rather than OrbiMed divesting its holdings.

Negatives

• The percentage decrease in beneficial ownership, even if due to dilution, means OrbiMed's relative influence has slightly diminished.
• The increase in outstanding shares implies dilution for existing shareholders, which can put downward pressure on per-share metrics.

Risks

• The Reporting Persons' investment strategy is subject to various factors including the Issuer's business, financial condition, results of operations, prospects, general economic and industry conditions, and securities market performance.
• Future actions by the Reporting Persons, including acquiring or disposing of shares, could impact the Issuer's stock price.
• The Issuer's ability to effect demand or S-3 registrations for OrbiMed's shares could be subject to market conditions and underwriter limitations.

Future Outlook

The Reporting Persons intend to continuously review their investment in ArriVent BioPharma based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire additional shares or dispose of existing holdings in the future, depending on their assessment.

Management Comments

• The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients.
• The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities.
• Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time.

Industry Context

This filing is specific to an institutional investor's stake in a biopharmaceutical company. While it doesn't directly discuss broader industry trends, the biopharma sector often sees significant institutional investment due to its high-growth potential and specialized nature. The increase in outstanding shares by ArriVent BioPharma is common in the biotech industry, where companies frequently raise capital to fund research, development, and clinical trials.

Corporate Governance

Related Party Transactions

• Carl L. Gordon, a director of the Issuer and a member of OrbiMed Advisors, is obligated to transfer any stock options or equity-based compensation received from the Issuer, or the economic benefit thereof, to OrbiMed Advisors, GP VIII, Advisors IV, and OAP GP IV. These entities will then ensure such benefits are provided to OPI VIII and OAP IV.

Stakeholder Impact

• Shareholders: The increase in outstanding shares implies dilution, which can reduce per-share earnings and ownership percentage for existing shareholders. However, it also suggests the company successfully raised capital, which could fund operations and growth.
• Management: The continued significant stake and board representation by OrbiMed indicate ongoing investor confidence and potential influence on strategic decisions.
• Creditors: A capital raise (implied by increased shares) could strengthen the company's balance sheet, potentially improving its credit profile.

Next Steps

• The Reporting Persons will continue to review their investment in ArriVent BioPharma, Inc.
• They may acquire or dispose of additional shares or other securities of the Issuer in the open market or privately negotiated transactions based on their ongoing review.
• The Issuer may be required to effect demand or S-3 registrations for OrbiMed's shares under the Investors' Rights Agreement, subject to certain conditions and limitations.

Key Dates

Recommendation

The filing primarily reports a technical adjustment in beneficial ownership percentage due to an increase in the issuer's outstanding shares, rather than a change in the investor's conviction or a divestment. OrbiMed maintains a substantial stake and board representation, which is generally a positive signal. However, the underlying dilution for existing shareholders could exert some downward pressure. Without further information on the purpose or terms of the share issuance, a "hold" recommendation is appropriate, suggesting investors maintain their current position while awaiting more comprehensive financial updates from ArriVent BioPharma.

Keywords

ArriVent BioPharma, OrbiMed Advisors, Schedule 13D, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceutical, Investment, Dilution, SEC Filing